Lv21
120 积分 2025-08-18 加入
Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials
5天前
已完结
Assessing the “Drug Loss” and “Drug Lag” for Rare Diseases in China: A Comparative Analysis with the United States (2001–2024)
13天前
已完结
A multi-dimensional comparative study of 505(b)(2) NDAs approved by FDA and Class 2 NDAs approved by NMPA from 2017 to 2023: Uncovering trends, characteristics, and regulation of modified new drugs
1个月前
已关闭
Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer
5个月前
已完结
FDA’s New Plausible Mechanism Pathway
6个月前
已完结
Characterization of studies considered and required under Medicare’s coverage with evidence development program
6个月前
已完结
Navigating Pharmaceutical Patent Term Extension System in China
6个月前
已完结
Global Analysis of Regulatory Frameworks and Drug Safety Standards in the Drug Approval Process
7个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
8个月前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
8个月前
已完结
皖公网安备34019202002308
